Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.
PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1/2 activity improved RAS-directed therapy, revealing a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable.
Lin Zhang, A. Bolomsky, Omar S. Al-Odat et al.
· Blood Cancer Discovery · 0 citations